Human CLDN19 adenoviral particles

The CLDN19 gene encodes the tight junction protein Claudin-19, a key component of tight junctions that plays a critical role in maintaining cell polarity and regulating paracellular permeability in epithelial and endothelial tissues. Claudin-19 is particularly abundant in the kidney, retina, and inner ear, where it participates in barrier formation and selective ion transport. Mutations in the CLDN19 gene are associated with severe clinical disease, including familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), as well as ocular diseases such as macular degeneration. Due to its important role in cell adhesion and homeostasis, CLDN19 has become a focus of research in kidney diseases and therapeutic interventions. Studying the expression and regulation of this gene is essential for understanding its pathological mechanisms and developing targeted therapies.

Human CLDN19 adenoviral particles are genetically engineered recombinant adenovirus designed to deliver the CLDN19 gene to target cells for functional studies or gene therapy applications. These particles take advantage of the high transduction efficiency and broad tropism of adenoviral vectors, ensuring stable gene expression in both dividing and non-dividing cells. Researchers have used these particles to study the role of CLDN19 in tight junction assembly, ion transport, and disease modeling, particularly in renal and retinal cell lines. In addition, CLDN19 adenoviral particles have therapeutic potential to correct the genetic defect in diseases such as familial hypertrophic neuropathic cholangitis (FHHNC) by restoring functional claudin-19 expression. Its safety profile, such as the deletion of viral replication genes, ensures minimal cellular toxicity, making it a valuable tool for preclinical studies.